EyePoint (EYPT) Treasury Shares (2017 - 2026)
EyePoint (EYPT) posted Treasury Shares of $1.7 million for Q1 2026, up 13.05% sequentially from $1.5 million in Q4 2025, and up 7.36% YoY from $1.6 million in Q1 2025.
EyePoint (EYPT) Treasury Shares (2017 - 2026) Analysis & Trends
EyePoint has reported Treasury Shares for 10 years, with the latest figure at $1.7 million in Q1 2026.
- Quarterly Treasury Shares rose 7.36% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (up 7.36% YoY) and the FY2025 annual result came in at $1.5 million, up 12.0% from the prior year.
- Treasury Shares improved to $1.7 million in Q1 2026 per EYPT's latest filing, from $1.5 million in the prior quarter.
- Over five years, Treasury Shares peaked at $1.7 million in Q1 2026 and troughed at $311017.0 in Q1 2023.
- A 5-year average of $1.1 million and a median of $1.3 million in 2023 frame the typical range for Treasury Shares.
- The sharpest annual moves came in 2023 and 2024: Treasury Shares slumped 44.42% in 2023, then jumped 351.15% in 2024.
- Over 5 years, Treasury Shares stood at $509170.0 in 2022, then soared by 161.84% to $1.3 million in 2023, then decreased by 1.32% to $1.3 million in 2024, then rose by 12.0% to $1.5 million in 2025, then increased by 13.05% to $1.7 million in 2026.
- According to Business Quant data, Treasury Shares over the past three periods registered $1.7 million, $1.5 million, and $1.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.08 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 92,219.00 |
| 10 | EyePoint | 1.25 Bn | 1.07 Bn | 507,000.00 | 1.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.61 Mn |
| Jun 30, 2026 | 1.61 Mn |
| Mar 31, 2026 | 1.67 Mn |
| Mar 31, 2026 | 1.67 Mn |
| Dec 31, 2025 | 1.47 Mn |
| Dec 31, 2025 | 1.47 Mn |
| Sep 30, 2025 | 1.48 Mn |
| Sep 30, 2025 | 1.48 Mn |
| Jun 30, 2025 | 1.52 Mn |
| Jun 30, 2025 | 1.52 Mn |
| Mar 31, 2025 | 1.55 Mn |
| Mar 31, 2025 | 1.55 Mn |
| Dec 31, 2024 | 1.32 Mn |
| Dec 31, 2024 | 1.32 Mn |
| Sep 30, 2024 | 1.33 Mn |
| Sep 30, 2024 | 1.33 Mn |
| Jun 30, 2024 | 1.38 Mn |
| Jun 30, 2024 | 1.38 Mn |
| Mar 31, 2024 | 1.40 Mn |
| Mar 31, 2024 | 1.40 Mn |